Anticancer Agents from Natural Products, Second Edition

Gordon M. Cragg, David G. I. Kingston, David J. Newman

October 10, 2011 by CRC Press
Reference - 767 Pages - 450 B/W Illustrations
ISBN 9781439813829 - CAT# K10713


Add to Wish List
FREE Standard Shipping!


    • Covers current drugs in advanced preclinical and clinical development, giving the book real value for scientists looking for information on the next generation of anticancer drugs
    • Emphasizes on the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities
    • Focuses on the development of effective drugs through antibody-directed targeted delivery of potent cytotoxins to tumor cells
    • Discusses novel drug discovery through combinatorial biosynthesis and genome mining
    • Authorship by leading scientists on each drug, including in some cases the drug developer or a close associate
    • Editorship by two scientists from the National Cancer Institute who have contributed enormously to natural product drug development, and by one of the leading researchers on Taxol® and other potential anticancer natural products


    The approach to drug discovery from natural sources has yielded many important new pharmaceuticals inaccessible by other routes. In many cases the isolated natural product may not be an effective drug for any of several reasons, but it nevertheless may become a drug through chemical modification or have a novel pharmacophore for future drug design. In summarizing the status of natural products as cancer chemotherapeutics, Anticancer Agents from Natural Products, Second Edition covers the:

    • History of each covered drug—a discussion of its mechanism on action, medicinal chemistry, synthesis, and clinical applications
    • Potential for novel drug discovery through the use of genome mining as well as future developments in anticancer drug discovery
    • Important biosynthetic approaches to "unnatural" natural products

    Anticancer Agents from Natural Products, Second Edition discusses how complex target-oriented synthesis—enabled by historic advances in methodology—has enormously expanded the scope of the possible. This book covers the current clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. It also reviews drug candidates currently in clinical development since many of these will be clinically used drugs in the future.

    Examples include the drugs etoposide and teniposide derived from the lead compound podophyllotoxin; numerous analogs derived from taxol; topotecan, derived from camptothecin; and the synthetic clinical candidates, E7389 and HTI-286, developed from the marine leads, halichondrin B and hemiasterlin.